한국형 우울장애 약물치료 알고리듬 (Ⅳ) : 우울장애의 아형 및 부작용에 따른 항우울제의 선택과 여성우울장애에서의 치료전략 = Korean Medication Algorithm for Depressive Disorder 2006 (Ⅳ) : The Choice of Antidepressant According to the Subtypes of Depression, Adverse Effects of Antidepressant and Treatment Strategies in Women

다국어 초록 (Multilingual Abstract)

Objectives : In 2002, the Korean Medication Algorithm Project for Major depressive Disorder (KMAP-MD) was published, but there has been a need for a guideline about detailed issues of depressive disorder. We revised KMAP-MDD andreestablished Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) in 2006.
Methods : A questionnaire had been developed by the executive committee for KMAP-DD. The review committee consisted of 101 experienced psychiatrists. From the total of 22 questions in the questionnaire, 7 questions were evaluated for these subjects . We classified the expert opinions to 3 categories according to its confidence interval; first, second and third line.
Results : SSRI and venlafaxine were the first line antidepressants (AD) for atypical and melancholic depression. For dysthymic disorder and minor depressive disorder, SSRI was recommended as the first line medications. Only AD medications was a preferred initial strategy for treating premenstrual dysphoric disorder, mild to moderate and severe non-psychotic postpartum depression. In severe psychotic postpartum depression, combination therapy of AD and atypical antipsychotics was the treatment of choice. SSRI was preferred when considering sedation, anticholinergic and cardiovascular adverse effects. Also, experts recommended mirtazapine against gastrointestinal adverse effects and bupropion in avoiding sexual dysfunction.
Conclusion : These results suggest that clinicians have to consider both clinical situations and drug adverse effects in the choice of antidepressant medications.

참고문헌 (Reference)

1 Rosenbaum JF, "Treatment response to serotonin reputake inhibitors in minor depression" 5 : 172-173, 1995

2 Marin H, "The management of fatigue in depressed pa-tients" 6 : 185-192, 2005

3 The Executive Commitee of Korean Medication Algorithm Project for Depressive Disorder, "The Korean medication guideline for de-pressive disorder 2006" Seoul: Jungangmunwha 2006

4 Altshuler LL, "The Expert Consensus Guidelines Series: Treatment of de-pression in Women 2001" (1-107) : 2001

5 Alexopoulos GS, "The Expert Consensus Guidelines Series: Pharmacotherapy of De-pressive Disorders in Older Patients 2001" (1-86) : 2001

6 Oxman TE, "Status of minor depression or dysthymia in primary care fol-lowing a randomized controlled treatment" 23 : 301-310, 2001

7 Mir S, "Sexual adverse events with new antidepresants" 22 : 438-441, 1998

8 Riva-Vazquez RA, "Sexual Dysfunction Asociated with Antidepresant Treatment" 31 : 641-651, 2000

9 Browne G, "Sertraline and/or interpersonal psychotherapy for patients with dys-thymic disorder in primary care: 6 month comparison with longitu-dinal 2-year folow-up of effectiveness and costs" 68 : 317-330, 2002

10 Amsterdam J.D, "Selective serotonin reputake inhibitor eficacy in severe and melancholic depression" 12 : 99-111, 1998

11 Devanand DP, "Randomized, double-blind, placebo-controled trial of fluo-xetine treatment for elderly patients with dysthymic disorder" 13 : 59-68, 2005

12 ACOG (American College of Obstetricians and Gynecologist), "Premenstrual syndrome" 2000.April.15

13 "Pharmacological characterization of selective serotonin re-uptake inhibitors" intclinpsychopharmacol1994;919-26

14 Ravindran AV, "Paroxetine in the treatment of dysthymic disorder without major depresion-eficacy, tolerability, and impact on quality of life" 16 : 300-, 2006

15 Connor K, "Modafinil for major depression with atypical features" 14 : 180-181, 2004

16 Guelfi JD, "Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features" 21 : 425-431, 2001

17 Rekers H, "Mirtazapine Lacks Typical SSRI-Related Adverse Efects" 6 : 47-, 1996

18 Cantilon M, "Melancholic depression: venlafa-xine vs fluoxetine" 11 : 196-, 2001

19 Freeman EW, "Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder" 18 : 453-468, 2004

20 Dimmock PW, "Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review" 365 : 1131-1136, 2000

21 Model JG, "Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline" 61 : 476-487, 1997

22 Wisner KL, "Clinical practice: postpartum depression" 347 : 194-199, 2002

23 Kennedy SH, "Clinical Guidelines for the Treatment of De-pressive Disorders" 46 : 5s-90s, 2007

24 Helerstein DJ, "Citalopram in the treatment of dysthymic disorder" 19 : 143-148, 2004

25 Bazire S, "Cardiovascular disease" Mark Allen Publishing: Devon, UK 178-182, 2000

26 Royal Australian and New Zealand Colege of Psychiatrists Clinical Practice Guidelines Team for Depresion, "Australian and New Zealand clinical practice guidelines for the treatment of depresion" 38 : 389-407, 2004

27 Murck H, "Atypical depression spectrum disorder - neurobiology and treatment" 15 : 227-241, 2003

28 Mayers AG, "Antidepressants and their effect on sleep" 20 : 533-559, 2005

29 Devanand DP, "An open treatment trial of venlafaxine for elderly patients with dysthymic disorder" 17 : 219-224, 2004

30 Lee MS, "Adequate Pharmacotherapy for Major Depressive Disorder in Korea Society" 1 : 27-42, 2003